Novartis AG (NVS)
After hours:
| Previous Close | 82.51 |
| Open | 83.19 |
| Bid | 83.12 x 1000 |
| Ask | 84.08 x 1000 |
| Day's Range | 82.72 - 83.69 |
| 52 Week Range | 74.09 - 94.26 |
| Volume | |
| Avg. Volume | 2,114,816 |
| Market Cap | 177.177B |
| Beta (5Y Monthly) | 0.47 |
| PE Ratio (TTM) | 24.02 |
| EPS (TTM) | 3.48 |
| Earnings Date | N/A |
| Forward Dividend & Yield | 3.47 (4.02%) |
| Ex-Dividend Date | Mar 09, 2023 |
| 1y Target Est | 104.25 |
- Zacks
Incyte (INCY) Gets CRL for Jakafi Extended-Release Tablets
The FDA issues a complete response letter to Incyte's (INCY) extended-release tablet formulation of Jakafi drug for the treatment of myelofibrosis, polycythemia vera and graft-versus-host disease.
- The Guardian
Novartis scraps cholesterol drug trial in blow to UK life sciences ambitions
Swiss firm’s withdrawal from Leqvio trial with NHS dents government plans to attract post-Brexit research and investment
- GlobeNewswire
Sandoz receives US FDA approval for biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation
Biosimilar Hyrimoz® (adalimumab-adaz) high-concentration formulation (HCF) approved for seven indications of reference medicine Humira®* With this approval, Sandoz adalimumab HCF biosimilar will offer US patients reduced injection volume in citrate-free formulationSandoz continues to expand patient access to much-needed medications, increase healthcare savings and fuel innovation through increased competition Basel, March 21, 2023 – Sandoz, a global leader in generic pharmaceuticals and biosimil
